Clinical trial

Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or…

NCT00135564 · GlaxoSmithKline, Industry · Completed

Key facts

NCT number NCT00135564
Title Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers
Official title Evaluate the Persistence and Immune Memory Induced by a Primary Vaccination Course With GSK Biologicals' MenC-TT (1 Formulation) & GSK Biologicals' Hib-MenC-TT (2 Formulations) or Meningitec™ in Healthy Toddlers Aged 12-15 Months Primed in Study 711202/001
Lead sponsor GlaxoSmithKline, Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Infections, Meningococcal
Intervention type Biological
Interventions MenC-TT, Hib-MenC-TT
Enrollment 500
Start date Jan 1, 2003
Primary completion Jul 1, 2003
Completion Jul 1, 2003
First posted Aug 26, 2005
Last update posted Sep 16, 2016

At a glance

  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies